Streetbeat News

Analyst Ratings

ORCL

Bernstein analyst Mark Moerdler maintains an Outperform rating on Oracle (ORCL) and raises the price target from $147 to $159.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:45 am

ZVRA

William Blair analyst Tim Lugo initiates coverage on Zevra Therapeutics (NASDAQ:ZVRA) with an Outperform rating, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:43 am

ORCL

Mizuho analyst Siti Panigrahi maintains a Buy rating on Oracle (NYSE:ORCL) and raises the price target from $140 to $160, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:42 am

DXCM

RBC Capital analyst Shagun Singh initiates coverage on DexCom (NASDAQ:DXCM) with an Outperform rating and a price target of $165.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:40 am

TBBB

Scotiabank analyst Hector Maya initiates coverage on BBB Foods (NYSE:TBBB) with a Sector Outperform rating and a price target of $33.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:38 am

TKNO

BTIG analyst Mark Massaro downgraded Alpha Teknova (NASDAQ:TKNO) from Buy to Neutral, indicating a change in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:35 am

NHI

BMO Capital analyst John Kim upgraded National Health Investors (NYSE:NHI) from Market Perform to Outperform with a new price target of $67.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:33 am

GTES

Keybanc analyst Jeffrey Hammond has maintained an Overweight rating on Gates Industrial Corp (GTES) and increased the price target from $18 to $21.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:29 am

ACAD

B of A Securities analyst Tazeen Ahmad maintains a Neutral rating on ACADIA Pharmaceuticals (ACAD) and lowers the price target from $33 to $30.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:26 am

EQT

B of A Securities analyst Doug Leggate maintains a Buy rating on EQT Corporation (NYSE:EQT) and raises the price target from $52 to $60.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:25 am